|Systematic (IUPAC) name|
|Mol. mass||271.40 g/mol|
| (what is this?)
Research into the use of cyclazocine for the treatment of bipolar patients with depression was undertaken by Fink and colleagues (1970). It showed that 8 out of 10 patients experienced moderate improvement.
Research during the 1960s and 1970s into the possible use of cyclazocine for management of pain, and later for assisting treatment of narcotic addiction was severely hampered by the drug's psychotomimetic, dysphoric, and hallucinatory effects.
Dosages of 1–3 mg were administered in the tests.
- Archer, S.; Glick, S. D.; Bidlack, J. M. (1996). "Cyclazocine Revisited". Neurochemical Research 21 (11): 1369–1373. doi:10.1007/BF02532378. PMID 8947927.
- Freedman, A. M.; Fink, M.; Sharoff, R.; Zaks, A. (1967). "Cyclazocine and Methadone in Narcotic Addiction" (pdf). The Journal of the American Medical Association 202 (3): 191–194. doi:10.1001/jama.1967.03130160065011. PMID 6072354.